Green Cross Cell Corporation Logo

Green Cross Cell Corporation

031390.KQ

(0.0)
Stock Price

38.550,00 KRW

0% ROA

0.64% ROE

0x PER

Market Cap.

0,00 KRW

0% DER

0% Yield

0.32% NPM

Green Cross Cell Corporation Stock Analysis

Green Cross Cell Corporation Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Green Cross Cell Corporation Fundamental Stock Analysis
# Analysis Rating
1 ROE

Unidentified ROE

2 ROA

Unidentified ROA

3 PBV

Unidentified ROA

4 DER

Unidentified DER

5 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

6 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

7 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Graham Number

Unidentified Graham Number

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Green Cross Cell Corporation Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Green Cross Cell Corporation Technical Stock Analysis
# Analysis Recommendation

Green Cross Cell Corporation Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Green Cross Cell Corporation Revenue
Year Revenue Growth
2012 856.575.203.000
2013 938.298.393.000 8.71%
2014 1.044.768.160.000 10.19%
2015 1.132.876.998.000 7.78%
2016 1.354.466.206.000 16.36%
2017 1.465.489.006.550 7.58%
2018 1.548.714.795.470 5.37%
2019 1.493.588.620.940 -3.69%
2020 1.719.325.649.720 13.13%
2021 1.840.558.602.630 6.59%
2022 2.079.559.970.670 11.49%
2023 2.145.373.215.600 3.07%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Green Cross Cell Corporation Research and Development Expenses
Year Research and Development Expenses Growth
2012 70.655.000.000
2013 72.961.000.000 3.16%
2014 75.014.000.000 2.74%
2015 95.507.000.000 21.46%
2016 109.210.000.000 12.55%
2017 103.749.000.000 -5.26%
2018 122.405.000.000 15.24%
2019 126.347.000.000 3.12%
2020 143.311.000.000 11.84%
2021 147.282.000.000 2.7%
2022 193.944.000.000 24.06%
2023 186.140.000.000 -4.19%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Green Cross Cell Corporation General and Administrative Expenses
Year General and Administrative Expenses Growth
2012 2.371.000.000
2013 2.672.000.000 11.26%
2014 2.976.000.000 10.22%
2015 118.721.598.230 97.49%
2016 135.528.304.350 12.4%
2017 146.965.518.000 7.78%
2018 168.302.123.000 12.68%
2019 153.229.050.050 -9.84%
2020 180.169.861.980 14.95%
2021 215.012.959.500 16.21%
2022 247.533.120.690 13.14%
2023 257.614.684.240 3.91%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Green Cross Cell Corporation EBITDA
Year EBITDA Growth
2012 105.954.261.000
2013 115.224.864.000 8.05%
2014 138.019.883.000 16.52%
2015 141.873.076.770 2.72%
2016 134.353.536.650 -5.6%
2017 153.168.957.000 12.28%
2018 96.594.045.000 -58.57%
2019 123.694.836.160 21.91%
2020 123.595.029.020 -0.08%
2021 148.442.224.500 16.74%
2022 148.876.431.310 0.29%
2023 125.309.005.720 -18.81%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Green Cross Cell Corporation Gross Profit
Year Gross Profit Growth
2012 273.579.842.000
2013 297.776.048.000 8.13%
2014 335.980.618.000 11.37%
2015 368.304.675.000 8.78%
2016 391.414.841.000 5.9%
2017 410.893.475.000 4.74%
2018 405.052.168.000 -1.44%
2019 424.488.886.211 4.58%
2020 528.891.891.000 19.74%
2021 626.899.184.000 15.63%
2022 696.017.717.000 9.93%
2023 669.575.689.960 -3.95%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Green Cross Cell Corporation Net Profit
Year Net Profit Growth
2012 -7.912.281.770
2013 43.549.742.880 118.17%
2014 56.760.787.880 23.27%
2015 65.420.806.930 13.24%
2016 47.176.642.180 -38.67%
2017 43.364.196.170 -8.79%
2018 18.465.406.570 -134.84%
2019 42.740.673.847 56.8%
2020 60.805.860.634 29.71%
2021 54.901.373.988 -10.75%
2022 32.489.635.158 -68.98%
2023 -36.740.651.800 188.43%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Green Cross Cell Corporation Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2012 -183
2013 974 118.79%
2014 1.245 21.77%
2015 1.439 13.48%
2016 1.039 -38.5%
2017 955 -8.8%
2018 407 -135.22%
2019 941 56.85%
2020 1.339 29.72%
2021 1.209 -10.75%
2022 716 -69.09%
2023 -781 191.67%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Green Cross Cell Corporation Free Cashflow
Year Free Cashflow Growth
2012 -38.725.393.850
2013 -97.763.935.890 60.39%
2014 -23.712.208.190 -312.29%
2015 -144.790.651.780 83.62%
2016 -160.663.908.790 9.88%
2017 -51.773.268.500 -210.32%
2018 -80.353.823.420 35.57%
2019 -131.278.307.810 38.79%
2020 -72.704.458.980 -80.56%
2021 -12.830.700.310 -466.64%
2022 23.941.250.960 153.59%
2023 -80.772.479.100 129.64%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Green Cross Cell Corporation Operating Cashflow
Year Operating Cashflow Growth
2012 36.796.180.230
2013 17.568.307.990 -109.45%
2014 54.542.863.230 67.79%
2015 7.035.743.480 -675.23%
2016 -805.469.520 973.5%
2017 144.482.443.820 100.56%
2018 37.643.839.290 -283.81%
2019 7.650.391.890 -392.05%
2020 35.772.090.490 78.61%
2021 103.769.151.070 65.53%
2022 97.156.791.410 -6.81%
2023 -59.145.184.750 264.27%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Green Cross Cell Corporation Capital Expenditure
Year Capital Expenditure Growth
2012 75.521.574.080
2013 115.332.243.880 34.52%
2014 78.255.071.420 -47.38%
2015 151.826.395.260 48.46%
2016 159.858.439.270 5.02%
2017 196.255.712.320 18.55%
2018 117.997.662.710 -66.32%
2019 138.928.699.700 15.07%
2020 108.476.549.470 -28.07%
2021 116.599.851.380 6.97%
2022 73.215.540.450 -59.26%
2023 21.627.294.350 -238.53%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Green Cross Cell Corporation Equity
Year Equity Growth
2012 972.827.321.350
2013 1.099.667.145.820 11.53%
2014 1.181.067.099.040 6.89%
2015 1.307.378.785.149 9.66%
2016 1.377.011.145.190 5.06%
2017 1.439.667.555.500 4.35%
2018 1.453.116.546.630 0.93%
2019 1.506.596.203.770 3.55%
2020 1.673.500.718.750 9.97%
2021 1.910.728.953.700 12.42%
2022 1.967.043.519.270 2.86%
2023 1.902.024.404.400 -3.42%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Green Cross Cell Corporation Assets
Year Assets Growth
2012 1.446.337.217.960
2013 1.624.124.362.980 10.95%
2014 1.790.874.896.420 9.31%
2015 2.058.661.120.090 13.01%
2016 2.249.277.258.810 8.47%
2017 2.560.695.917.810 12.16%
2018 2.628.599.972.130 2.58%
2019 2.773.868.507.080 5.24%
2020 3.241.202.077.380 14.42%
2021 3.496.833.926.960 7.31%
2022 3.592.060.734.920 2.65%
2023 3.625.737.605.500 0.93%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Green Cross Cell Corporation Liabilities
Year Liabilities Growth
2012 473.509.896.610
2013 524.457.217.160 9.71%
2014 609.807.797.380 14%
2015 751.282.334.940 18.83%
2016 872.266.113.620 13.87%
2017 1.121.028.362.310 22.19%
2018 1.175.483.425.510 4.63%
2019 1.267.272.303.310 7.24%
2020 1.567.701.358.630 19.16%
2021 1.586.104.973.260 1.16%
2022 1.625.017.215.650 2.39%
2023 1.723.713.201.090 5.73%

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Green Cross Cell Corporation Dividends
Year Dividends Growth

Green Cross Cell Corporation Profile

About Green Cross Cell Corporation

Green Cross Cell Corporation develops, manufactures, and sells anti-cancer immune cell therapy for liver cancer in South Korea and internationally. It also offers cord blood storage and immune cell bank services. The company was founded in 1992 and is headquartered in Yongin, South Korea.

CEO
Employee
274
Address
107 Correctional Building
Yongin-Si,

Green Cross Cell Corporation Executives & BODs

Green Cross Cell Corporation Executives & BODs
# Name Age

Green Cross Cell Corporation Competitors